STAT Plus: Dyne Therapeutics and three other startups got venture funding a year ago. Will it be enough to get them through Covid-19?
How a venture-backed startup gets its money is suddenly more fraught than it used to be.
As the Covid-19 pandemic effectively shuttered cities (and clinical trials), biotech executives looked for ways to keep their companies on track. Some took a hard look at their budgets Others shipped medications to the homes of enrolled clinical trial participants — and many, many people shared what they’ve learned. Some executives may be hoping that their venture capital investors will be flush enough to support them; for companies working on a Covid-related project, new funding sources may be an option.
